WGS
Bearish signalScored 2026-09-22 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
GeneDx Holdings Corp.
- Nom
- GeneDx Holdings Corp.
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- NASDAQ
- Capitalisation
- $1.7B
- Employés
- 1,300
- PDG
- Katherine A. Stueland
- Site web
- http://www.genedx.com
- Marché
- AIDXBLLNCSTLFLGTIMDXMDXH
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 14 193 titres (~1 300 735,38 $ US)
- Insiders
- Stueland Katherine
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$858,002
Avg sell (VWAP, 90d window) $90.63 vs last close $88.40 (-2.5%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-16
- Liquidity
- Liquid $61,061,783/day · 20d vol
- Last synced
-
2026-09-25 21:11:05
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-16 | Feeley Kevin | Sell · S | 1,079 | $99.00 | $106,816 | Form 4 |
| 2026-09-16 | Stueland Katherine | Sell · S | 3,039 | $99.00 | $300,846 | Form 4 |
| 2026-09-09 | Feeley Kevin | Sell · S | 1,285 | $84.22 | $108,220 | Form 4 |
| 2026-09-09 | Stueland Katherine | Sell · S | 3,692 | $84.22 | $310,932 | Form 4 |
| 2026-09-01 | Feeley Kevin | Sell · S | 372 | $83.84 | $31,188 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-09-22 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
WGS presents a mixed picture: while operational improvements and promising genomic sequencing catalysts (NPC GenomeComplete launch, rapid sequencing study) are encouraging, the weak catalyst score of 25 with no…
The first sentence of the analysis written for WGS on 2026-09-22 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 2.46 · operating margin -2.8% — readings disagree
Suggested stop 82.95, nearest stored support minus 0.5 ATR(6.2% under the last close). Reward/risk to the next stored resistance is 1.63. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 69.7% | 63.6% | 44.4% | -11.4% | -7.8% | |
| Ebit Margin | -4.4% | -16.2% | -84.0% | -194.9% | -114.3% | |
| Ebitda Margin | 1.5% | -9.1% | -67.4% | -169.7% | -104.0% | |
| Operating Profit Margin | -2.8% | -7.6% | -89.2% | -284.5% | -210.3% | |
| Pretax Profit Margin | -4.9% | -17.2% | -87.2% | -254.8% | -115.6% | |
| Continuous Operations Profit Margin | -4.9% | -17.1% | -86.8% | -233.9% | -115.6% | |
| Net Profit Margin | -4.9% | -17.1% | -86.8% | -233.9% | -115.6% | |
| Bottom Line Profit Margin | -4.9% | -17.1% | -86.8% | -233.9% | -115.6% | |
| Current Ratio | 2.463 | 3.611 | 3.100 | 1.474 | 4.774 | |
| Quick Ratio | 2.335 | 3.417 | 2.951 | 1.379 | 4.444 | |
| Solvency Ratio | 0.016 | -0.174 | -0.745 | -1.680 | -1.347 | |
| Cash Ratio | 0.964 | 1.554 | 1.695 | 0.952 | 3.955 | |
| Price To Earnings Ratio | -178.164 | -39.619 | -0.380 | -0.162 | -1.964 | |
| Price To Earnings Growth Ratio | 2.857 | 0.541 | 0.004 | 0.006 | -0.016 | |
| Forward Price To Earnings Growth Ratio | 2.857 | 0.541 | 0.004 | 0.006 | -0.016 | |
| Price To Earnings Diluted Ratio | -178.164 | -39.619 | -0.380 | -0.162 | -1.964 | |
| Price To Earnings Diluted Growth Ratio | 2.857 | 0.541 | 0.004 | 0.006 | 0.040 | |
| Price To Book Ratio | 11.349 | 8.428 | 0.293 | 0.351 | 1.242 | |
| Price To Sales Ratio | 8.180 | 6.767 | 0.330 | 0.380 | 2.272 | |
| Price To Free Cash Flow Ratio | 245.230 | -60.813 | -0.360 | -0.267 | -2.282 | |
| Price To Operating Cash Flow Ratio | 105.095 | -72.532 | -0.371 | -0.279 | -2.531 | |
| Debt To Assets Ratio | 0.266 | 0.277 | 0.286 | 0.141 | 0.059 | |
| Debt To Equity Ratio | 0.493 | 0.474 | 0.525 | 0.304 | 0.085 | |
| Debt To Capital Ratio | 0.330 | 0.321 | 0.344 | 0.233 | 0.078 | |
| Long Term Debt To Capital Ratio | 0.220 | 0.175 | 0.188 | 0.024 | 0.028 | |
| Financial Leverage Ratio | 1.850 | 1.710 | 1.837 | 2.149 | 1.428 | |
| Working Capital Turnover Ratio | 2.826 | 2.291 | 2.112 | 1.042 | 0.879 | |
| Operating Cash Flow Ratio | 0.306 | -0.520 | -3.063 | -2.212 | -1.880 | |
| Operating Cash Flow Sales Ratio | 0.078 | -0.093 | -0.889 | -1.360 | -0.897 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.429 | 1.193 | 1.032 | 1.045 | 1.109 | |
| Debt Service Coverage Ratio | 0.587 | -9.004 | -272.704 | -24.801 | -35.297 | |
| Interest Coverage Ratio | -4.648 | -7.656 | 0.000 | -208.186 | -157.372 | |
| Short Term Operating Cash Flow Coverage Ratio | 3.720 | 0.000 | -362.469 | -29.358 | -55.699 | |
| Operating Cash Flow Coverage Ratio | 0.219 | -0.245 | -1.504 | -4.138 | -5.798 | |
| Capital Expenditure Coverage Ratio | 1.750 | -5.190 | -31.544 | -22.284 | -9.162 | |
| Dividend Paid And Capex Coverage Ratio | 1.750 | -5.190 | -31.544 | -22.284 | -9.162 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 534.926 | -75.887 | -0.637 | -0.073 | -0.518 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 69.7% | ▲6.1% | ▲38.0% |
| Ebit Margin | -4.3% | ▲11.9% | ▲78.4% |
| Ebitda Margin | 1.6% | ▲10.6% | ▲71.3% |
| Operating Profit Margin | -2.8% | ▲4.8% | ▲116.1% |
| Pretax Profit Margin | -4.9% | ▲12.3% | ▲91.0% |
| Continuous Operations Profit Margin | -4.9% | ▲12.2% | ▲86.8% |
| Net Profit Margin | -4.9% | ▲12.2% | ▲86.8% |
| Bottom Line Profit Margin | -4.9% | ▲12.2% | ▲86.8% |
| Current Ratio | 2.463 | ▼-1.148 | ▼-0.621 |
| Quick Ratio | 2.335 | ▼-1.082 | ▼-0.570 |
| Solvency Ratio | 0.016 | ▲0.190 | ▲0.802 |
| Cash Ratio | 0.964 | ▼-0.590 | ▼-0.860 |
| Price To Earnings Ratio | -178.164 | ▼-138.546 | ▼-134.106 |
| Price To Earnings Growth Ratio | 2.857 | ▲2.315 | ▲2.178 |
| Forward Price To Earnings Growth Ratio | 2.857 | ▲2.315 | ▲2.178 |
| Price To Earnings Diluted Ratio | -178.164 | ▼-138.546 | ▼-134.106 |
| Price To Earnings Diluted Growth Ratio | 2.857 | ▲2.315 | ▲2.167 |
| Price To Book Ratio | 11.349 | ▲2.921 | ▲7.016 |
| Price To Sales Ratio | 8.181 | ▲1.414 | ▲4.595 |
| Price To Free Cash Flow Ratio | 245.230 | ▲306.043 | ▲208.929 |
| Price To Operating Cash Flow Ratio | 105.095 | ▲177.627 | ▲99.219 |
| Debt To Assets Ratio | 0.267 | ▼-0.011 | ▲0.060 |
| Debt To Equity Ratio | 0.493 | ▲0.019 | ▲0.117 |
| Debt To Capital Ratio | 0.330 | ▲0.009 | ▲0.069 |
| Long Term Debt To Capital Ratio | 0.220 | ▲0.045 | ▲0.093 |
| Financial Leverage Ratio | 1.850 | ▲0.140 | ▲0.056 |
| Working Capital Turnover Ratio | 2.826 | ▲0.536 | ▲0.997 |
| Operating Cash Flow Ratio | 0.306 | ▲0.825 | ▲1.779 |
| Operating Cash Flow Sales Ratio | 0.078 | ▲0.171 | ▲0.710 |
| Free Cash Flow Operating Cash Flow Ratio | 0.429 | ▼-0.764 | ▼-0.533 |
| Debt Service Coverage Ratio | 0.587 | ▲9.591 | ▲68.831 |
| Interest Coverage Ratio | -4.648 | ▲3.008 | ▲70.924 |
| Short Term Operating Cash Flow Coverage Ratio | 3.720 | ▲3.720 | ▲92.481 |
| Operating Cash Flow Coverage Ratio | 0.219 | ▲0.464 | ▲2.512 |
| Capital Expenditure Coverage Ratio | 1.750 | ▲6.939 | ▲15.036 |
| Dividend Paid And Capex Coverage Ratio | 1.750 | ▲6.939 | ▲15.036 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 534.926 | ▲610.813 | ▲443.364 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.50B | $2.07B | $66.9M | $89.2M | $482.0M | |
| Enterprise value | $3.54B | $2.10B | $86.9M | $28.9M | $114.3M | |
| EV / Sales | 8.29x | 6.87x | 0.43x | 0.12x | 0.54x | |
| EV / Op. cash flow | 106.51x | -73.62x | -0.48x | -0.09x | -0.60x | |
| EV / Free cash flow | 248.52x | -61.72x | -0.47x | -0.09x | -0.54x | |
| EV / EBITDA | 534.93x | -75.89x | -0.64x | -0.07x | -0.52x | |
| Net debt / EBITDA | 7.09x | -1.12x | -0.15x | 0.15x | 1.67x | |
| Current ratio | 2.46x | 3.61x | 3.10x | 1.47x | 4.77x | |
| Income quality | -1.58x | 0.55x | 1.02x | 0.58x | 0.78x | |
| Graham net-net | -$1 | $0 | -$1 | -$11 | $83 | |
| Tax burden | 99.5% | 99.3% | 99.5% | 91.8% | 100.0% | |
| Interest burden | 113.7% | 106.1% | 103.8% | 130.7% | 101.2% | |
| Working capital | $159.4M | $143.2M | $123.5M | $68.3M | $382.3M | |
| Invested capital | $410.5M | $360.3M | $355.5M | $339.3M | $445.0M | |
| Return on assets | -3.7% | -12.5% | -42.0% | -100.7% | -44.3% | |
| Operating ROA | -2.4% | -5.5% | -37.5% | -121.5% | -110.7% | |
| Return on tangible assets | -5.4% | -20.0% | -71.4% | -153.1% | -44.3% | |
| Return on equity | -6.8% | -21.3% | -77.1% | -216.4% | -63.2% | |
| Return on invested capital | -2.5% | -6.3% | -49.3% | -148.8% | -97.8% | |
| Return on capital employed | -2.6% | -6.4% | -50.2% | -166.5% | -98.5% | |
| Earnings yield | -0.6% | -2.5% | -262.9% | -615.7% | -50.9% | |
| Free cash flow yield | 0.4% | -1.6% | -278.0% | -374.0% | -43.8% | |
| Capex / Op. cash flow | 57.1% | -19.3% | -3.2% | -4.5% | -10.9% | |
| Capex / Depreciation | 75.4% | 25.0% | 15.9% | 24.1% | 95.3% | |
| Capex / Sales | 4.4% | 1.8% | 2.8% | 6.1% | 9.8% | |
| SG&A / Sales | 56.0% | 55.2% | 96.1% | 144.1% | 150.2% | |
| R&D / Sales | 16.8% | 15.0% | 28.8% | 36.7% | 49.6% | |
| Stock comp / Sales | 7.5% | 3.0% | -0.2% | 17.9% | 103.4% | |
| Intangibles / Total assets | 31.9% | 37.8% | 41.2% | 34.2% | 0.0% | |
| Days sales outstanding | 63d | 45d | 59d | 67d | 46d | |
| Days payables outstanding | 7d | 26d | 33d | 64d | 71d | |
| Operating cycle | 103d | 80d | 88d | 86d | 99d | |
| Cash conversion cycle | 96d | 54d | 54d | 22d | 28d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-20 Kevin Feeley Sells 3,728 Shares of GeneDx (NASDAQ:WGS) Stock GeneDx Holdings Corp. (NASDAQ: WGS - Get Free Report) CFO Kevin Feeley sold 3,728 shares of GeneDx stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total value of $363,890.08. Following the sale, the chief financial officer directly owned 44,945 shares in the
- 2026-09-11 Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation Tempus AI, Inc. (NASDAQ: TEM) today announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical inform
- 2026-09-09 GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C.
- 2026-09-08 3 Promising Genomics Stocks in the Spotlight in 2026 Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
- 2026-09-01 GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree GAITHERSBURG, Md.--(BUSINESS WIRE)--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity.
- 2026-08-26 GeneDx Holdings Corp (WGS) Shares Surge 3.3% -- What GF Score of 65 Tells Investors On August 26, 2026, GeneDx Holdings Corp (WGS) shares rose 3.3%, bringing the current price to $90.28. The stock is trading within a 52-week range of $32.21 to
- 2026-08-26 Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside Bears have piled into a familiar batch of volatile, heavily bet-against names, and nowhere is the wager bigger than on Venture Global, Inc. (NYSE:VG). More than 80% of its float is sold short, the steepest ratio on the market''s current top-10 short-interest list, per Benzinga Pro data.
- 2026-08-24 GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children''s [url="]GeneDx[/url] (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced new data publish
- 2026-08-24 GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children''s GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Seattle Children''s show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children.
- 2026-08-19 Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates? GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.